BONE TARGETING AGENTS IN PREVENTION OF SKELETAL RELATED EVENTS IN METASTATIC CANCERS OF SOLID TUMOURS : AN ECONOMIC EVALUATION

Hanin Farhana K.¹, Atikah S.¹, Sharifa Ezat WP.², Zafar A.³, and Junainah S.¹

¹Malaysian Health Technology Assessment Section (MaHTAS), Ministry of Health Malaysia ²Universiti Kebangsaan Malaysia, ³Universiti Malaysia Sarawak



5th International Conference on Public Health 2019 (ICOPH 2019)

"Promoting Global Health Equity towards a Sustainable Future"

10th - 12th July 2019 | Kuala Lumpur | Malaysia

Introduction

Skeletal related events (SRE)

Skeletal complications from bone metastases

- Spinal cord compression
 - Pathological fracture
- Need for bone radiation and bone surgery
 - Hypercalcaemia
 - Bone pain

Approximately 70% patients with Stage IV cancer affected by

bone metastases

most common cancers that metastases to bone

F



What we already know

Bone targeting agents (**biphosphonates** and **denosumab**) has been used as **treatment** for bone metastases with SREs

NICE : **biphosphonates** can be offered to patients with lung ca, advanced breast ca, metastatic ca with spinal cord compression

MOH Drug Formulary (2018) :

- Ibandronic acid and Denosumab was approved for treatment of post-menopausal osteoporosis
- Zoledronic acid was approved for prevention of SREs only in patients with multiple myeloma involving multiple bone lesions



What we want to know

Are bone targeting agents safe, effective & cost-effective in preventing skeletal-related events among patients with metastatic cancers of solid tumours?



From SR and meta-analysis

BTAs significantly delayed timeto-first SREs and reduced the risk of first & subsequent SREs in all cancers except NSCLC

01


03



Among all biphosphonates, Zoledronic acid has the highest effectiveness in delaying first SREs in breast and lung cancer

No significant difference in terms of SRE prevention between 12-weekly and 4weekly IV Zoledronic Acid 04 Denosumab was superior than ZA in delaying the time to first SRE (HR=0.82, 95%CI 0.78, 0.87) and reducing the risk of first SRE (RR=0.83, 95%CI 0.77, 0.87)

Source : Health Technology Assessment Section (MaHTAS) MDD, Ministry of Health Malaysia. Bone targeting agents in preventing skeletal related events in metastatic cancers of solid tumours and economic evaluation. 2018. MOH/P/PAK/413.18(RR)-e







to assess the **cost-effectiveness of bone targeting agents** in prevention of skeletal-related events in metastatic cancer of solid tumours



to calculate the **incremental cost-effectiveness ratio (ICER)** of Zoledronic Acid and Denosumab with current best supportive care in prevention of SREs among patients with metastatic solid tumours



to estimate the **financial implications** when patients with bone metastases secondary to solid tumours transitioned from usual care (no prophylaxis) to bone targeting agent as SRE-prophylaxis

Methodology & Model Structure







Methodology

Literature-based Markov model Population : primary solid tumour with bone mets

Seven health states in two disease conditions: stable & progressive

Perspective : Ministry of Health Malaysia Transition cycle : 3-month Time horizon : lifetime






Simulated Clinical Pathways

- All patients entered the model after confirming presence of bone metastases (cancer with metastases, no SRE) and managed according to standard care (with or without BTA).
- In the cohorts of patients receiving bone targeting agent, it was given as prevention and treatment of SRE. Tablet calcium supplementation was also given.
- Patients would either remain in stable metastatic disease or having disease progression before experiencing the first episode of SRE and/or subsequent SRE.

- The health outcome and economic impact related to drug-induced severe adverse events were not included in the model due to its rarity (<1%).³
- In patients receiving ZA, renal profile was performed prior to each treatment in view of possible complication of renal toxicity.
- All patients received palliative care. Follow-up in oncology specialists clinic was 3-monthly.
- Death was only possible due to metastatic cancer and not other causes.





Assumptions

- The same BTA is given as prevention and treatment of SRE in the cohort (no switch of treatment once patient has SRE).
- The quality of life benefits (utility) of all bone targeting agents were assumed to be similar.
- Utility values in disease progression states are lower than in stable metastases.
- SRE did not change the mortality rate.

- No more than one SRE could occur within each cycle (maximum SRE that may occur in a year is 4 times)
- The type of subsequent SRE was not dependent on the first SRE.
- Stable and progressive metastases states incur the same cost.
- Average cost of SRE-related treatments is the same (regardless first or subsequent SRE.)


Clinical Parameters

Parameter	Usual care	ZA	Denosumab	Reference
Median time to first SRE in months (SD)	11 (0.8)	17.1 (1.1)	20.7 (1.6)	1, 2, 4, 5
Skeletal morbidity rate	3.05	1.71	1.20	1, 3
Risk of hypocalcaemia	-	6%	13%	4
Increased risk of having first SRE and subsequent SRE due to progression	2.14	2.14	2.14	1
Transitional probabilities	Transitional probabilities			
From stable metastases to disease progression	0.221	0.221	0.221	1
First SRE among patients without progression	0.245	0.115	0.096	1, 2
Subsequent SRE among patients without progression	0.355	0.167	0.137	1,2
From any health states to death	0.271	0.271	0.271	1

ITAS

 \mathbf{M}

al



utility Inputs

- Obtained from a time trade-off study by Dranitsaris and Hsu (1999), the only published estimate of utilities for bone targeting agents and SRE for patients with advanced breast cancer receiving Pamidronate (also used by other EE).
- Compared with utility value from **ACTION study** on health-related QoL among cancer survivors in Southeast Asia including Malaysia.

Health states	Base-case value	95%CI	Reference
No SRE, receive BTA	0.64	0.53 - 0.76	3, 6, 7
No SRE, receive usual care	0.56	0.45 - 0.68	3, 6, 7
SRE, receive BTA	0.46	0.37 - 0.54	3, 6, 7
SRE, receive usual care	0.31	0.23 - 0.38	3, 6, 7
Stage IV with progressive disease	0.39	0.33 - 0.45	9
Stage IV at diagnosis	0.65	SD = 0.24	8


Cost & Resource Data

Cost description	Base case estimate	Reference / Source
Tablet calcium carbonate 500mg (per month)	RM 180.00	MOH Consumer Price Guide ¹⁰ (2018)
Renal profile (per test)	RM 5.00 (third class charge)	MOH Investigation Charges ¹¹ (2018)
Total cost IV Zoledronic acid 4mg (per dose)	RM 472.00	National Cancer Institute, Lee WC et al (2016) ¹²
Total cost SC Denosumab 120mg (per dose)	RM 1,239.14	National Cancer Institute, Lee WC et al (2016) ¹²
Stable / Progressive Stage IV disease (per year)	RM 21,830.77	MalaysianDRG (severity illness 2), Dranitsaris G et al (2011) ¹³ , Zainal R et al (2014) ¹⁴
Average cost of first SRE related treatment	RM 5,132.04	MalaysianDRG (severity illness 2), Hwa YS et al (2011) ¹⁵

ITAS

 \mathbf{M}

aF



Sensitivity Analysis


- **Deterministic** : 1-way sensitivity analysis
- Input parameters for SA:
 - annual discounting rate (0-5%)
 - transition probability of subsequent SRE in BTA group (per cycle)
 - utility values for usual care and BTA groups
 - cost of first SRE-related managements
 - cost of stable / progressive Stage IV disease
- Varying input parameters :
 - specified range / standard deviation
 - UL & LL of 95% confidence interval



Results








Base-Case Results

Strategies	Total cost per patient	Total QALY per patient	Increment. cost	Increment. QALY	ICER (compared to usual care)
Usual care	RM 32,544.36	1.6235	-	-	-
ZA	RM 37,314.89	2.5836	RM 4,770.53	0.9601	RM 4,968.87
Denosumab	RM 57,231.09	2.7582	RM 24,686.73	1.1348	RM 21,754.66

*over the lifetime of the patients cohort (approximately 7 years)

1 GDP per capita per QALY gained for Malaysia (USD 10,500 = MYR 42,688)

The lower the ICER, the better



Sensitivity Analysis Results

Parameters	95% CI limit / Range / SD	ICER of lower value input	ICER of higher value input
Annual discounting rate	0 – 5%	RM 5,174.74	RM 4,600.12
Transition probability of subsequent SRE in patients without progression (zoledronic acid group)	SD = 0.019	RM 5,026.56	RM 4,915.89
Utility values for usual care and zoledronic acid groups	Refer to Table 2	RM 6,131.09	RM 4,681.52
Cost of first SRE-related managements	RM 1,845 - RM 8,745	RM 4,478.36	RM 5,273.47
Total cost of stable and progressive Stage IV disease	RM 17,710 - RM 31,552	RM 3,834.01	RM 6,858.80

Tornado Diagram : 1-way sensitivity analysis







* Central axis = base-case ICER (RM 4,968.87)

Financial Implications

Transition from usual care (no BTA) to Zoledronic Acid as SRE-prophylaxis in primary solid tumor patients with bone metastases



*(Malaysian National Cancer Registry Report 2007-2011)



Financial Implications

12-weekly Zoledronic Acid

RM 4,289.82

per patient per year

RM 8.8 million

Total financial implication per year

4-weekly Zoledronic Acid

RM 9,081.90


per patient per year


RM 18.7 million

Total financial implication per year



Scenario Analysis






Strategy


12-weekly ZA (ori) SREprophylaxis to these patients first before widening the coverage

RM 4.6 million Total financial implication per year

Total budget impact following transition from usual care to different strategies of SRE-prophylaxis with zoledronic acid



Proportion of patients switching from usual care to prophylactic ZA



Conclusion



The use of bone targeting agents in preventing skeletal-related events among Stage IV solid tumour patients with bone metastases is a cost-effective strategy.



The most cost-effective option was 12-weekly intravenous Zoledronic Acid, yielding an ICER of RM 4,968.87 per QALY gained



The estimated total financial implications for this strategy with 100% potential patients coverage (n=2,054) was **RM 8.8 million per year**.

References

- 1. Oster G, Lamerato L, Glass AG, et al. Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems. Support Care Cancer. 2013;21(12):3279-3286.
- 2. Chern B, Joseph D, Joshua D, et al. Bisphosphonate infusions: patient preference, safety and clinic use. Support Care Cancer. 2004;12(6):463-466.
- 3. Botteman M, Barghout V, Stephens J, et al. Cost effectiveness of bisphosphonates in the management of breast cancer patients with bone metastases. Ann Oncol. 2006 Jul;17(7):1072-82.
- 4. Xie J, Namjoshi M, Wu EQ, et al. Economic evaluation of Denosumab compared with Zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. J Manag Care Pharm. 2011 Oct;17(8):621-43.
- 5. Saad F, Gleason DM, Murray R, et al; Zoledronic acid Prostate Cancer Study Group. Long-term efficacy of Zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004 Jun 2;96(11):879-82.
- 6. DePuy V, Anstrom KJ, Castel LD, et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer. 2007;15(7):869-876.
- 7. Dranitsaris G, Hsu T. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer. Support Care Cancer. 1999 Jul;7(4):271-9.
- 8. Nafees B, Patel C, Ray D, e al. An Assessment of Health-State Utilities in Metastatic Breast Cancer in the United Kingdom. Value in Health. 2016 May 1;19(3):A157.
- 9. ACTION Study Group. Health-related quality of life and psychological distress among cancer survivors in Southeast Asia: results from a longitudinal study in eight low- and middle-income countries. BMC Med. 2017 Jan 13;15(1):10.
- 10. Consumer Price Guide. Pharmaceutical Services Programme, Ministry of Health Malaysia. Available at: https://www.pharmacy.gov.my/v2/en/apps/drug-price. (Accessed : 17 July 2018)





- 11. MOH Investigation Charges. Ministry of Health Malaysia. Available at: http://www.moh.gov.my/english.php/pages/view/155 . (Accessed : 17 July 2018)
- 12. Lee WC, Haron MR, Yu KL, et al. Economic analysis of intravenous vs. subcutaneously administered trastuzumab for the treatment of HER2+ early breast cancer in Malaysia. Advances in Breast Cancer Research. 2016 Jan 11;5(01):1.
- 13. Dranitsaris G, Truter I, Lubbe MS, et al. Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia. Malays J Med Sci. 2011 Oct;18(4):32-43.
- 14. Zainal R, Mahat M. Estimating The Costs Of Specialist Out-Patient Services In A Public Hospital. Value Health. 2014 Nov;17(7):A790.
- 15. Hwa YS, Shatar AK, Hashim H. THE SOCIOECONOMIC IMPACTS OF BREAST CANCER ON BREAST CANCER PATIENTS IN PENANG. Kajian Malaysia: Journal of Malaysian Studies. 2011 Dec 1;29(2).
- 16. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12 (20 Suppl):6243s-6249s
- 17. Fizazi K, Carducci M, Smith M, et al. Denosumab versus Zoledronic acid for treatment of bone metastases in men with castrationresistant prostate cancer: a randomised, double-blind study. Lancet. 2011;377(9768):813-822.







haninfarhana@moh.gov.my haninfarhana@gmail.com



